NCCN guidelinesĀ® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines Article Report uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Lymphoma, Non-Hodgkin

abstract

  • Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.

authors

publication date

  • March 2017

Research

keywords

  • Report

Identity

PubMed ID

  • 28275031

Additional Document Info

start page

  • 293

end page

  • 311

volume

  • 15

number

  • 3